3 models fit Haemonetics Corporation Common Stock and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Large premium(i)Silver70
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionHaemonetics Corporation Common Stock (HAE)
Fair value (3 models)
$67.64
ACCE price target
$116
Rating
Overvalued
Horizon
12 months
Fair value published on 19 Oct 2026, 17:05 CEST; previously $76.47 since 4 Oct 2026, 00:00 CEST.
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Rating published on 19 Oct 2026, 17:05 CEST.
Price used: $119 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
75.2% above
-42.9% to fair value
ACCE score
62
out of 100
Analysts
82% buy
11 covering
P/E
56.7x
forward 20.3x
1-year return
+130.8%
Dividend yield
0.00%
Haemonetics Corporation Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Haemonetics makes the blood collection and processing systems that hospitals and plasma centres use to separate and handle donated blood, including its plasma collection devices and the Terumo-licensed cell processing platforms it sells into surgical settings. The moat is installed base and consumables: once a plasma centre runs on its NexSys-type disposables and service contracts, switching costs are high and recurring revenue follows the volume of donations processed. Growth is tied to plasma collection volumes, which the company has guided to rise as global demand for plasma-derived therapies keeps climbing. At a 17.9% operating margin and 59.3% gross margin, the business is profitable, but revenue growth of 5.6% is modest for a device name and the trailing P/E of 58.6 reflects depressed GAAP earnings, while the forward P/E of 20.3 shows the market is pricing a recovery in earnings. The question for a PM is whether margin expansion from that recovery is credible at a 11.2% ROE, which is worth testing in the filings before any further work.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Stretched valuation versus model
Price trades 75.2% above the model fair value of $67.64, and trailing P/E is 57.1 against a forward P/E of 20.5, so earnings must recover sharply to justify the price.
moderate
Leverage and thin earnings growth
Debt/Equity is 1.54 and earnings grew only 2.9% YoY against 5.6% revenue growth, while net margin of 7.1% leaves little cushion for a slowdown.
moderate
Rising short interest
Short interest stands at 7.8% of float, a meaningful bet against the stock that could add volatility around any earnings miss.
AI research notes
AI-assisted·How I use AIWritten Oct 20, 2026 · figures from 2026-10-20 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last twelve months reached $260M, showing the business turns sales into real cash.
Management cut the diluted share count by 6.7% last year, lifting each shareholder's slice of the company.
Eleven of thirteen analysts...
Why it could disappoint
The share price sits 75.2% above the model fair value of $67.64, leaving little margin for error.
Debt equals 1.54 times equity, which limits room for acquisitions that the growth story now depends on.
Trailing earnings multiple of 57.1x against a forward 20.5x shows reported profits lag the cleaner estimates.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where HAE's valuation models land
Price
$118.51
Model fair value
$67.64
Model range
$42.27 to $128
Fair value $67.64
Price $119
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores